GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyper Corporation Inc (XKRX:065650) » Definitions » Cyclically Adjusted Price-to-FCF

Hyper (XKRX:065650) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Hyper Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hyper Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Hyper's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyper Cyclically Adjusted Price-to-FCF Chart

Hyper Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hyper Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hyper's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Hyper's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyper's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyper's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hyper's Cyclically Adjusted Price-to-FCF falls into.



Hyper Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Hyper's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Hyper's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-18.824/118.8477*118.8477
=-18.824

Current CPI (Mar. 2024) = 118.8477.

Hyper Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -15.758 99.353 -18.850
201409 -1.264 99.608 -1.508
201412 -44.775 99.098 -53.698
201503 -29.746 99.720 -35.452
201506 -22.965 100.050 -27.280
201509 20.245 100.110 24.034
201512 26.519 100.220 31.448
201603 -14.686 100.560 -17.357
201606 0.353 100.790 0.416
201609 -27.736 101.460 -32.489
201612 -0.450 101.560 -0.527
201703 -33.847 102.850 -39.112
201706 -10.365 102.610 -12.005
201709 2.075 103.490 2.383
201712 -8.613 102.990 -9.939
201803 14.814 104.100 16.913
201806 -24.233 104.130 -27.658
201809 -2.483 105.650 -2.793
201812 -23.887 104.350 -27.206
201903 -36.406 104.490 -41.408
201906 -23.507 104.880 -26.638
201909 -31.419 105.200 -35.495
201912 -57.647 105.120 -65.175
202003 -50.455 105.540 -56.817
202006 11.186 104.870 12.677
202009 -10.175 106.200 -11.387
202012 -47.508 105.765 -53.384
202103 -272.981 107.357 -302.198
202106 100.612 107.579 111.151
202109 -37.351 108.759 -40.816
202112 80.496 109.676 87.227
202203 -40.362 111.806 -42.904
202206 -94.397 114.083 -98.340
202209 -65.105 114.831 -67.382
202212 101.894 115.200 105.120
202303 6.877 116.550 7.013
202306 -33.573 117.140 -34.062
202309 30.450 119.111 30.383
202312 -26.967 118.848 -26.967
202403 -18.824 118.848 -18.824

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hyper  (XKRX:065650) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Hyper Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Hyper's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyper (XKRX:065650) Business Description

Traded in Other Exchanges
N/A
Address
Woolim A-1401, 583, Yangcheon-ro, Gangseo-gu, Seoul, KOR, 07547
Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Hyper (XKRX:065650) Headlines

No Headlines